Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2023 | The prognostic value of CD34+CD38- leukemic stem cell frequency in AML

In this video, Jacqueline Cloos, PhD, Amsterdam UMC, Amsterdam, The Netherlands, shares some insights into the prognostic impact of CD34+CD38- leukemic stem cells (LSCs) in patients with acute myeloid leukemia (AML) observed in the HOVON-SAKK-132 trial (EudraCT 2013-002843-2). This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Disclosure (institute) received research funding from Takeda, DC-one, Genentech, Janssen, Novartis, Merus and royalties from Navigate and BD Biosciences.